Stockreport

Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros’ Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)

Omeros Corporation  (OMER) 
Last omeros corporation earnings: 3/2 04:03 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.omeros.com
PDF SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the closing of the asset sale and licensing transaction between Omeros and Novo Nordisk f [Read more]